Billiontoone (NASDAQ:BLLN) Issues Earnings Results

Billiontoone (NASDAQ:BLLN) released its quarterly earnings results on Wednesday. The company reported $0.34 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.01 by $0.33, Zacks reports. The firm’s revenue for the quarter was up 83.8% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.39) EPS.

Here are the key takeaways from Billiontoone’s conference call:

• Q1 financials were strong — revenue grew 84% YoY to $108.4M with 44% test volume growth, a 73% gross margin, 16% GAAP operating margin, and $537M cash, delivering profitability and positive cash flow.
• Market access and pricing momentum — BillionToOne is now in‑network with Anthem and UnitedHealthcare, reaching ~300 million contracted lives, and ASPs rose 28% YoY to $571, prompting raised 2026 revenue guidance to $450–$465M.
• Product differentiation — the launch of Unity Confirm, the company’s non‑invasive fetal cell–based confirmation assay, showed initial 100% concordance versus invasive diagnostics and is positioned to strengthen Unity as a frontline prenatal offering.
• Oncology ramp shows momentum (oncology revenue nearly 5x to $10.7M and tumor‑naive MRD on track), but longer‑term upside depends on achieving Medicare coverage for Northstar Response and scaling to improve oncology margins.
• Near‑term limits and risks — BillionToOne expects Unity Confirm to address only ~0.5–1% of patients (so minimal direct revenue), its prospective concordance study may take 1–3 years, and accounts receivable rose due to new payer contracts, which could affect short‑term cash conversion.

Billiontoone Stock Up 1.9%

Shares of NASDAQ BLLN opened at $81.40 on Thursday. Billiontoone has a twelve month low of $61.96 and a twelve month high of $138.70. The business’s fifty day moving average price is $77.51. The company has a market capitalization of $3.74 billion and a P/E ratio of 387.62. The company has a debt-to-equity ratio of 0.12, a current ratio of 11.69 and a quick ratio of 11.32.

Analyst Ratings Changes

Several research firms have recently issued reports on BLLN. Guggenheim dropped their price target on shares of Billiontoone from $120.00 to $100.00 and set a “buy” rating for the company in a research note on Monday, March 30th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Billiontoone in a research note on Friday, May 1st. BTIG Research dropped their price target on shares of Billiontoone from $160.00 to $140.00 and set a “buy” rating for the company in a research note on Thursday, March 5th. Wall Street Zen raised shares of Billiontoone from a “hold” rating to a “buy” rating in a research note on Saturday, March 7th. Finally, Wells Fargo & Company dropped their price target on shares of Billiontoone from $110.00 to $90.00 and set an “equal weight” rating for the company in a research note on Thursday, March 5th. Six analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $126.71.

Hedge Funds Weigh In On Billiontoone

A number of hedge funds have recently bought and sold shares of the company. T. Rowe Price Investment Management Inc. bought a new position in Billiontoone during the fourth quarter worth $8,277,000. Invesco Ltd. bought a new position in Billiontoone during the fourth quarter worth $15,535,000. XTX Topco Ltd bought a new position in Billiontoone during the fourth quarter worth $1,692,000. Quadrature Capital Ltd bought a new position in Billiontoone during the fourth quarter worth $614,000. Finally, Perceptive Advisors LLC bought a new position in Billiontoone during the fourth quarter worth $5,959,000.

Billiontoone Company Profile

BillionToOne (NASDAQ: BLLN) is a molecular diagnostics company that develops and commercializes high-precision genetic testing solutions based on single-molecule counting technology. The company’s platform is designed to detect and quantify rare genetic variants and chromosomal abnormalities from cell-free DNA, with a primary focus on applications in prenatal screening and other clinical genetic tests where sensitivity and specificity at very low allele fractions are critical.

BillionToOne’s offerings center on assay development and clinical testing workflows that enable non-invasive prenatal testing (NIPT) and targeted molecular diagnostics.